The U.S. Food and Drug Administration approved Cytokinetics’ first American medicine for obstructive hypertrophic cardiomyopathy, ending a multi‑decade effort by the muscle‑biology focused biotech. The approval clears Myqorzo for patient use and positions Cytokinetics to begin commercial sales in the U.S. in late January, management said. The lead sentence of the filing and approval centers on a targeted cardiac indication: obstructive hypertrophic cardiomyopathy, an inherited condition that narrows the heart’s outflow tract. Myqorzo’s clearance gives Cytokinetics an on‑market product to fund further R&D and compete with established therapies, including a Bristol Myers Squibb competitor approved in 2022. Investors and market watchers should note this is the company’s first U.S. approval and a key de‑risking milestone that changes Cytokinetics’ business profile from development‑stage to commercial entrant. Clinical details and long‑term safety data will drive physician uptake and payer decisions after launch.